Revenue from ScripsAmerica's Diabetes Patient Supply Program Tops $103,000 in February
Revenue from ScripsAmerica's Diabetes Patient Supply Program Tops $103,000 in February
TYSONS CORNER, Va., March 4, 2015 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC) today announced that the Company's diabetes patient supply program generated $103,673 in revenue during the month of February 2015.
Through this program, ScripsAmerica's wholly owned subsidiary, Main Avenue Pharmacy, provides diabetes patients in designated US states with medical supplies that are available through a physician's prescription and usually covered by medical insurance and Medicare. Medical supplies included in this program include meters, test strips, swabs, pens, lancing devices and lancets.
Main Avenue Pharmacy works directly with manufacturers and suppliers to provide quality diabetic medical supplies and stores medical equipment inventory if necessary.
"The Company's diabetic supply program began generating an ancillary revenue stream in December of last year that will add to Main Avenue Pharmacy's prescription drug revenue and increase ScripsAmerica's shareholder value. The program quickly reached the initial milestone of enrolling 500 patients as recently announced and we are pleased to now report that it has generated over $100,000 last month," commented CEO of ScripsAmerica, Bob Schneiderman.
"Management has great confidence that the revenue from this diabetic supply program will experience a healthy rate of growth in 2015 and increasingly contribute to Main Avenue's success," concluded Schneiderman.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Seal Point Consulting, LLC
888-959-7095
ir@sealpointconsulting.com
(MORE TO FOLLOW) Dow Jones Newswires
March 04, 2015 08:00 ET (13:00 GMT)
Revenue from ScripsAmerica's Diabetes Patient Supply Program Tops $103,000 in February
TYSONS CORNER, Va., March 4, 2015 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC) today announced that the Company's diabetes patient supply program generated $103,673 in revenue during the month of February 2015.
Through this program, ScripsAmerica's wholly owned subsidiary, Main Avenue Pharmacy, provides diabetes patients in designated US states with medical supplies that are available through a physician's prescription and usually covered by medical insurance and Medicare. Medical supplies included in this program include meters, test strips, swabs, pens, lancing devices and lancets.
Main Avenue Pharmacy works directly with manufacturers and suppliers to provide quality diabetic medical supplies and stores medical equipment inventory if necessary.
"The Company's diabetic supply program began generating an ancillary revenue stream in December of last year that will add to Main Avenue Pharmacy's prescription drug revenue and increase ScripsAmerica's shareholder value. The program quickly reached the initial milestone of enrolling 500 patients as recently announced and we are pleased to now report that it has generated over $100,000 last month," commented CEO of ScripsAmerica, Bob Schneiderman.
"Management has great confidence that the revenue from this diabetic supply program will experience a healthy rate of growth in 2015 and increasingly contribute to Main Avenue's success," concluded Schneiderman.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Seal Point Consulting, LLC
888-959-7095
ir@sealpointconsulting.com
(MORE TO FOLLOW) Dow Jones Newswires
March 04, 2015 08:00 ET (13:00 GMT)
